📊 IMMX Key Takeaways
Is Immix Biopharma, Inc. (IMMX) a Good Investment?
Immix Biopharma is an early-stage pharmaceutical company with minimal revenue ($20M) and severe operating losses (-$10.8M), producing negative margins of -54% and unsustainable negative free cash flow of -$9.8M annually. While the fortress balance sheet with $79.3M in cash and zero debt provides 8+ years of operational runway, current fundamentals reveal a company burning cash with no evidence of profitability trajectory without significant revenue expansion or cost restructuring.
Immix Biopharma has a strong, debt-free balance sheet with ample cash to fund operations for multiple years, providing flexibility to advance its programs. However, profitability is distant with substantial operating losses and negative free cash flow, and the durability/quality of revenue remains unclear. Hold pending evidence of sustained revenue traction and improving operating efficiency.
Why Buy Immix Biopharma, Inc. Stock? IMMX Key Strengths
- Fortress balance sheet with $79.3M cash and zero debt eliminating financial distress risk
- Exceptional liquidity position (8.76x current ratio) providing substantial operational runway and flexibility
- Some revenue generation ($20M) indicates product commercialization has initiated beyond pure R&D stage
- Robust cash position (~$94M) and 10x liquidity
- Debt-free with low liabilities relative to assets
- Initial $20M revenue indicates some commercial/licensing traction
IMMX Stock Risks: Immix Biopharma, Inc. Investment Risks
- Severe operating unprofitability with -54% operating margin indicating fundamental business model unsustainability at current scale
- Continuous negative free cash flow (-$9.8M annually) despite small revenue base suggests structural cost issues requiring resolution
- Pharmaceutical sector inherent risks including regulatory approval uncertainty, clinical trial failures, patent challenges, and competitive landscape threats
- Large operating losses and -123% FCF margin
- Unclear revenue sustainability and lack of gross margin visibility
- Potential need for future capital if burn accelerates
Key Metrics to Watch
- Revenue growth rate and gross margin expansion demonstrating commercialization traction and unit economics improvement
- Operating cash burn trajectory and cash runway depletion timeline necessitating future capital raises
- Pipeline advancement stage, regulatory milestones, and approval probability of key development candidates driving long-term value
- Operating cash flow (quarterly burn)
- Revenue growth and mix (recurring vs. milestone)
Immix Biopharma, Inc. (IMMX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 8.76x current ratio provides a solid financial cushion.
IMMX Profit Margin, ROE & Profitability Analysis
IMMX vs Healthcare Sector: How Immix Biopharma, Inc. Compares
How Immix Biopharma, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Immix Biopharma, Inc. Stock Overvalued? IMMX Valuation Analysis 2026
Based on fundamental analysis, Immix Biopharma, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Immix Biopharma, Inc. Balance Sheet: IMMX Debt, Cash & Liquidity
IMMX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Immix Biopharma, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.76 indicates the company is currently unprofitable.
IMMX Revenue Growth, EPS Growth & YoY Performance
IMMX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $20.0M | -$4.5M | $-0.15 |
| Q3 2025 | $20.0M | -$7.1M | $-0.24 |
| Q2 2025 | $20.0M | -$4.4M | $-0.15 |
| Q1 2025 | $20.0M | -$4.5M | $-0.15 |
| Q3 2024 | $20.0M | -$4.3M | $-0.23 |
| Q2 2024 | $20.0M | -$3.6M | $-0.15 |
| Q1 2024 | $20.0M | -$2.5M | $-0.18 |
| Q3 2023 | $20.0M | -$1.5M | $-0.11 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Immix Biopharma, Inc. Dividends, Buybacks & Capital Allocation
IMMX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Immix Biopharma, Inc. (CIK: 0001873835)
📋 Recent SEC Filings
❓ Frequently Asked Questions about IMMX
What is the AI rating for IMMX?
Immix Biopharma, Inc. (IMMX) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (HOLD) with 67% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are IMMX's key strengths?
Claude: Fortress balance sheet with $79.3M cash and zero debt eliminating financial distress risk. Exceptional liquidity position (8.76x current ratio) providing substantial operational runway and flexibility. ChatGPT: Robust cash position (~$94M) and 10x liquidity. Debt-free with low liabilities relative to assets.
What are the risks of investing in IMMX?
Claude: Severe operating unprofitability with -54% operating margin indicating fundamental business model unsustainability at current scale. Continuous negative free cash flow (-$9.8M annually) despite small revenue base suggests structural cost issues requiring resolution. ChatGPT: Large operating losses and -123% FCF margin. Unclear revenue sustainability and lack of gross margin visibility.
What is IMMX's revenue and growth?
Immix Biopharma, Inc. reported revenue of $20.0M.
Does IMMX pay dividends?
Immix Biopharma, Inc. does not currently pay dividends.
Where can I find IMMX SEC filings?
Official SEC filings for Immix Biopharma, Inc. (CIK: 0001873835) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is IMMX's EPS?
Immix Biopharma, Inc. has a diluted EPS of $-0.18.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is IMMX a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Immix Biopharma, Inc. has a SELL rating with 67% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is IMMX stock overvalued or undervalued?
Valuation metrics for IMMX: ROE of -12.0% (sector avg: 15%), net margin of -50.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy IMMX stock in 2026?
Our dual AI analysis gives Immix Biopharma, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is IMMX's free cash flow?
Immix Biopharma, Inc.'s operating cash flow is $-9.8M, with capital expenditures of $32.5K. FCF margin is -49.3%.
How does IMMX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -50.4% (avg: 12%), ROE -12.0% (avg: 15%), current ratio 8.76 (avg: 2).